Royalty Pharma plc (RPRX) Stock: Price, Forecast & Analyst Target
Royalty Pharma plc (RPRX) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $68.67 (-0.01%), as of the Nov 18, 2026 trading session; market cap $39.5B.
Educational signal · not a buy or sell recommendation · How to read this
Royalty Pharma plc · RPRX · NASDAQ · Healthcare · Medical Pharmaceuticals
Research dated 2026-09-12: Royalty Pharma buys biopharmaceutical royalty rights and funds drug innovation; it owns cash flow claims on therapies rather than operating as a conventional medicine manufacturer. Its appeal and risk meet at the same point: whether portfolio receipts can support new royalty purchases, dividends, and a debt-heavy capital structure without sustained pressure on liquidity.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Royalty Pharma (RPRX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 8 of the last 8 reports
- Altman Z 2.49 · Piotroski F 6
- ROE 12.1% · ROA 5.4% · current ratio 1.29
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 74 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 73 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $68.67 | |
| Change on the day | -0.01% | |
| 52-week range | $37.31–$70.37 | |
| Market capitalisation | $39.5B | — |
| Price / earnings (trailing) | 41.12 | |
| Shares traded on the day | 3.19M | |
| Beta (volatility vs the S&P 500) | 0.41 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Royalty Pharma (RPRX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Royalty Pharma (RPRX), and what does it report?
Short answer · as of
Royalty Pharma purchases economic interests in marketed therapies and development-stage candidates across several therapeutic areas.
Research dated 2026-09-12.
Its healthcare classification places it alongside pharmaceutical companies, but its revenue comes from royalty assets rather than selling medicines it manufactures.
Financial Royalty Assets generate nearly all reported segment revenue, with Royalty Income, Other contributing a much smaller portion. The income statement records accounting revenue and profit from this portfolio, while operating cash flow captures cash generation; the latest series shows that those measures do not always move together.
What do the latest results show for Royalty Pharma (RPRX)?
Research dated 2026-09-12.
Quarterly revenue advanced from the prior period, yet gross profit, operating profit, net result, and diluted earnings all fell sharply. Research and development expense increased, while selling, general, and administrative expense remained elevated, so the latest top-line gain did not translate into comparable earnings.
Recent earnings releases have shifted from revenue shortfalls to revenue and earnings beats. Management has also raised guidance and continues to describe the longer-run growth profile as strong and low volatility, but that claim sits beside pronounced quarterly profit swings and must be judged separately from estimate comparisons.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $609M | $284M | $0.66 (diluted) |
| Q4 FY2025 | $622M | $214M | $0.50 (diluted) |
| Q1 FY2026 | $631M | $295M | $0.67 (diluted) |
| Q2 FY2026 | $674M | $18M | $0.04 (diluted) |
What are the financial strengths and risks for Royalty Pharma (RPRX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained substantial throughout the reported window, with no capital expenditure recorded, reflecting the capital-light nature of owning royalty interests. Trailing margins and free-cash-flow yield also point to strong portfolio economics, while recurring dividends return part of that cash to shareholders.
Balance-sheet flexibility is more constrained than cash generation alone suggests. Cash and short-term investments declined materially across the reported window before recovering in the latest period, and total debt remains far above cash and investments. Weaker receipts from underlying therapies or disappointing progress among development-stage candidates would therefore meet continuing financial obligations from a less comfortable liquidity position.
What should you watch next at Royalty Pharma (RPRX)?
Short answer · as of
Current published price targets run low $66.00 · high $67.00 · consensus $66.50 · median $66.50 against a quoted price of $68.67 (as of Nov 18, 2026).
Research dated 2026-09-12.
At the scheduled earnings release, compare reported revenue and earnings with expectations, but give greater weight to whether operating cash flow remains durable and the latest cash recovery continues. Recent estimate beats raised expectations; they did not remove the gap between liquid resources and debt.
Research and development expense, administrative expense, operating profit, and net result deserve close attention after their latest swings. Management’s raised guidance and low-volatility growth claim would gain support from sustained revenue, cash conversion, and earnings progress rather than an isolated favorable comparison with forecasts.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Royalty Pharma compare with its peers?
Short answer
Royalty Pharma's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Conventional biopharmaceutical companies depend on their own research, approvals, manufacturing, and commercialization. Royalty Pharma instead acquires or funds economic rights tied to therapies developed and sold by others, spreading its portfolio across marketed products and development candidates.
The small employee base, absence of reported capital expenditure, and high margins fit a scalable financial-asset model more closely than a laboratory or manufacturing network. Scientific underwriting, partnering, deal selection, and capital allocation are therefore central operating capabilities, while leverage makes the price and funding of royalty acquisitions especially consequential.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| Royalty Pharma (RPRX) — this page | $68.67 | $39.5B | 73 |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $66.00 – $67.00
- Consensus target
- $66.50
- Median target
- $66.50
Consensus record · Captured .
Measured against a quoted price of $68.67 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 44
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 16
- Other transactions
- 28
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RPRX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.12% | $27.69M | Added +116.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Royalty Pharma (RPRX)?
Common Questions About RPRX (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Financial Royalty Assets dominate Royalty Pharma’s revenue?
Acquired royalty interests, rather than conventional product sales, produce nearly all segment revenue. Therapy-level cash economics and acquisition discipline are therefore more informative than manufacturing volume.
How can Royalty Pharma grow without launching its own medicines?
Royalty receipts can expand as partnered therapies generate more sales or as Royalty Pharma acquires and funds additional rights. Development-stage candidates add potential future royalty streams, though their contribution depends on clinical and commercial progress.
What could break Royalty Pharma’s low-volatility growth claim?
Weak royalty receipts, setbacks among development-stage candidates, or continued swings in expenses and reported profit would challenge that claim. Persistent liquidity pressure alongside substantial debt would make such operating disappointments more consequential.
How should investors reconcile Royalty Pharma’s cash generation with its debt?
Operating cash flow is strong and reported capital expenditure is absent, but debt greatly exceeds cash and investments. That cash generation can support dividends and royalty purchases, yet it does not eliminate the importance of disciplined capital allocation and financial obligations.
What is the RPRX stock price today?
The last price recorded for Royalty Pharma plc (RPRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RPRX price target?
The analyst consensus price target for Royalty Pharma plc (RPRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold RPRX
Funds in our ETF coverage that list RPRX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Eventide High Dividend ETF (ELCV) | 3.10% | |
| Global X - Adaptive U.S. Factor ETF (AUSF) | 2.21% |